Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow of -CN¥9.07M in Q4 FY2025

Q4 FY2025 financing cash flow was -CN¥9.07M. Over 3 fiscal years it compounded at +33.9% a year.

Context

  • Financing cash flow amounted to 27.8% of revenue in FY2025, up 15.9 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥9.07M+81.4% QoQ
Last fiscal yearDec 2025
CN¥32.31M+246.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+246.0%——
3-year CAGR+33.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CNY · from the cash flow

Latest · FY2025
32.31M CNY
Year-over-year change
+246.0%

Financing Cash Flow vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +246.0% is the 2nd highest of 9, against a peer median of -7.8%.
  • Financing cash flow amounts to 27.8% of revenue for ZYBT, versus a peer median of 268.5%.
ZYBT Competitors
Financing Cash Flow for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$38.95M USD-57.9%—519.7%
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥32.31M CNY+246.0%+33.9%27.8%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$29.19M CAD+55.7%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$23.71M CAD+114.9%+16.7%—
PDEXPro-Dex, Inc.LTM Mar 2026$11.23M USD-1124.4%-28.2%15.0%
APYXApyx Medical CorporationLTM Mar 2026$9.64M USD+42.3%+253.4%17.2%
TILInstil Bio, Inc.LTM Mar 2026$7.06M USD+255.3%-53.4%—
SERASera Prognostics, Inc.LTM Mar 2026$504K USD-99.1%+2110.8%884.2%
EXOZeXoZymes, Inc.LTM Mar 2026$2.81K USD-100.0%——
Peer median (excluding ZYBT) —-7.8%+16.7%268.5%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.47M55.74M37.51M13.47M(82.97M)
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
Deferred Income Tax(358K)(1.09M)758K924K11.1M
Stock-Based Compensation00000
Change in Working Capital(33.71M)(66.82M)(20.49M)(977K)44.83M
Accounts Receivables(40.91M)(47.38M)38.05M11.31M61.41M
Inventory(12.34M)(12.33M)(12.9M)(5.88M)6.25M
Accounts Payables17.63M(9.67M)(35.61M)(404K)(3.36M)
Other Working Capital1.91M2.56M(10.03M)(6M)(19.47M)
Other Non-Cash Items3.4M10.7M6.5M3.47M14.42M
Operating Cash Flow31.81M17.34M48.18M41.05M13.33M
Capital Expenditures(26.4M)(27.33M)(11.6M)(27.77M)(12.63M)
Acquisitions (Net)00000
Purchases of Investments00(1.22M)00
Sales of Investments00000
Other Investing Activities(7.21M)0(3.15M)(14.08M)(11.62M)
Investing Cash Flow(26.27M)(27.33M)(11.77M)(27.67M)(12.63M)
Debt Repayment8M34.88M24.97M(2.74M)(12.09M)
Common Stock Issued000043.08M
Common Stock Repurchased00000
Dividends Paid(11.05M)(21.43M)(39.45M)(16.02M)0
Other Financing Activities0(1)(4.5M)(3.37M)1.32M
Financing Cash Flow(3.05M)13.46M(18.98M)(22.13M)32.31M
Effect of Forex Changes000168K(1.29M)
Net Change in Cash2.49M3.46M17.44M(8.58M)31.73M
Free Cash Flow5.41M(9.99M)36.58M13.27M703K

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.